NO964200D0 - Treatment of autoimmune disease using oral tolerance and / or Th2-enhancing cytokines - Google Patents

Treatment of autoimmune disease using oral tolerance and / or Th2-enhancing cytokines

Info

Publication number
NO964200D0
NO964200D0 NO964200A NO964200A NO964200D0 NO 964200 D0 NO964200 D0 NO 964200D0 NO 964200 A NO964200 A NO 964200A NO 964200 A NO964200 A NO 964200A NO 964200 D0 NO964200 D0 NO 964200D0
Authority
NO
Norway
Prior art keywords
treatment
autoimmune disease
oral tolerance
enhancing cytokines
cytokines
Prior art date
Application number
NO964200A
Other languages
Norwegian (no)
Other versions
NO964200L (en
Inventor
Howard L Weiner
Youhai Chen
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of NO964200L publication Critical patent/NO964200L/en
Publication of NO964200D0 publication Critical patent/NO964200D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO964200A 1994-04-08 1996-10-03 Treatment of autoimmune disease using oral tolerance and / or Th2-enhancing cytokines NO964200D0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
US33252494A 1994-10-31 1994-10-31
PCT/US1995/004512 WO1995027500A1 (en) 1994-04-08 1995-04-07 TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES

Publications (2)

Publication Number Publication Date
NO964200L NO964200L (en) 1996-10-03
NO964200D0 true NO964200D0 (en) 1996-10-03

Family

ID=26919544

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964200A NO964200D0 (en) 1994-04-08 1996-10-03 Treatment of autoimmune disease using oral tolerance and / or Th2-enhancing cytokines

Country Status (10)

Country Link
EP (1) EP0752879A4 (en)
JP (1) JPH09511990A (en)
KR (1) KR970702067A (en)
AU (1) AU695883B2 (en)
BR (1) BR9507452A (en)
CA (1) CA2187345A1 (en)
HU (1) HUT76101A (en)
IL (1) IL113301A0 (en)
NO (1) NO964200D0 (en)
WO (1) WO1995027500A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4278296A (en) * 1994-10-25 1996-05-15 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US6537810B1 (en) 1996-04-23 2003-03-25 President And Fellows Of Harvard College Methods for regulating T cell subsets by modulating transcription factor activity
US5958671A (en) 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
EP0939826A2 (en) * 1996-08-15 1999-09-08 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
US6022697A (en) * 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
WO1998037917A1 (en) * 1997-02-28 1998-09-03 Enzo Therapeutics, Inc., A Fully Owned Subsidiary Of Enzo Biochem, Inc. Novel processes implementing selective immune down regulation (sidr)
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
JP2003532618A (en) * 1998-05-19 2003-11-05 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド Cells, nervous system-specific antigens and their uses
WO2001068124A2 (en) 2000-03-15 2001-09-20 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
JP4986361B2 (en) 2000-05-24 2012-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ Stroke prevention method by induction of tolerance to E-selectin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190750A (en) * 1990-03-09 1993-03-02 Asahi Kasei Kogyo Kabushiki Kaisha Methods for the treatment of demyelinating disease, uveitis, or graft-versus-host disease using tnf
IL100402A0 (en) * 1990-12-19 1992-09-06 Schering Corp Use of il-4 to enhance immune response to immunogens in vaccines
ES2190784T3 (en) * 1992-02-28 2003-08-16 Autoimmune Inc SUPPRESSION OF AUTOIMMUNE DISEASES BY SPECTING ANTIGENS.
ES2131122T3 (en) * 1992-10-01 1999-07-16 Schering Corp USE OF IL-10 TO PREVENT INSULIN DEPENDENT DIABETES MELLITUS.
SG52402A1 (en) * 1992-12-22 1998-09-28 Univ Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins

Also Published As

Publication number Publication date
IL113301A0 (en) 1995-07-31
HU9602751D0 (en) 1996-11-28
BR9507452A (en) 1997-08-05
HUT76101A (en) 1997-06-30
NO964200L (en) 1996-10-03
CA2187345A1 (en) 1995-10-19
AU695883B2 (en) 1998-08-27
EP0752879A4 (en) 1999-07-21
KR970702067A (en) 1997-05-13
WO1995027500A1 (en) 1995-10-19
EP0752879A1 (en) 1997-01-15
JPH09511990A (en) 1997-12-02
AU2246795A (en) 1995-10-30

Similar Documents

Publication Publication Date Title
NO964200D0 (en) Treatment of autoimmune disease using oral tolerance and / or Th2-enhancing cytokines
NO992641D0 (en) Mixtures and Methods for the Treatment or Prevention of Inflammatory Diseases
GB9609932D0 (en) Use of IL-12 and IFN alpha for the treatment of infectious diseases
EP0963219A4 (en) Manipulations of nitrosative and oxidatives stress in the treatment of disease
NO933240D0 (en) Arrangement and preparation of toothbrush
NO20002846L (en) Inhalation device and method of the same
FI971822A0 (en) Recognition of speech
DK0621974T3 (en) Surgical and / or clinical apparatus
NO984094D0 (en) Discharge reactor and use of the same
NO964199D0 (en) Treatment of autoimmune disease using oral tolerance and / or type I interferon
NO971900D0 (en) Mixtures and treatment of multiple sclerosis
BR9707613A (en) Mixtures free of polypholic derivatives process of preparing mixtures i and ii medications and use of mixtures
NO20001412D0 (en) Compositions and Methods in the Treatment of Respiratory Disorders
NO983512D0 (en) Means for the treatment and prevention of AIDS
NO984836D0 (en) Substituted benzylamines and their use in the treatment of depression
NO890643L (en) PROCEDURE FOR TREATMENT OF EXHAUST AND EXHAUST.
NO973193D0 (en) Collagen-based methods and formulations for the treatment of immune system-mediated diseases
DK508586D0 (en) DEVILABLE AND USEFUL FILTER ORGAN
ZA9511021B (en) Plasma expanders and blood substitutes
PL322002A1 (en) Variants of human dnase i
NO985068D0 (en) Vaccines for the treatment of lymphoma and leukemia
DE69634044D1 (en) HUMAN CYCLIN I AND THE DAFUER ENCODING GEN
ITRM940210A1 (en) PROCEDURE FOR THE PURIFICATION OF POLYCARBUNATE AND POLYESTERCARBONATE SOLUTIONS
NO950033D0 (en) Integration of telemetry and sonar technology
UA25336A (en) METHOD OF TREATMENT OF VENTURAL DISEASE OF THE REMOVAL AND DUODY

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application